Home > Back to Publisher > Report Information

Countering Generic and Biosimilar Threats

Cutting Edge Information
June 1, 2010
246 Pages - SKU: CIGQ2750204

Abstract Table of Contents Related Reports

Prepare for generic competition and protect brand revenues:

According to IMS Health, global pharmaceutical sales approached a staggering $800 billion in 2009. At the same time, global sales of generic drugs grew 3.6% to $83 billion. To retain market share in the battle against generics, brands must devise a well-rounded strategy. But knowing which moves to make - and when - is no easy task, and decisions on how much to invest in a counter-generics strategy can make or break a brand's fortunes.

Countering Generic and Biosimilar Threats is your go-to resource for prioritizing and fine-tuning your counter-generics strategy. No other resource delivers this much information - combining benchmarks and industry insights - with such depth. Pore over analysis of 12 counter-generics tactics; comb through recent case studies to see how other brand teams have implemented these tactics; and peruse brand profiles to understand, at a glance, how other teams have mapped out their strategies. With this information you can:

Design a multifaceted, diverse generics defense strategy
Use counter-generics task forces to drive strategy forward while building institutional knowledge
Implement tried and true tactics that have proven successful in the months or years leading to patent expiration
Quickly implement strategies that are low-cost, but high-impact
Retain market share in the face of generic competition
Learn the differences and similarities between biosimilar and counter-generics tactics

CEI's research finds that over 40% of teams wait to start until four years before patent expiry to begin preparing for generics. While developing this study, we specifically aimed to address misperceptions and problems that are obstacles to effective planning, including the challenges posed by limited time and budgets. Generics defense is crucial for a branded drug at any point in its lifecycle - it's never too early or too late to think about this critical challenge.

Countering Generic and Biosimilar Threats

Share this report

Other tasks

Research Assistance

Related Markets

Manufacturing, Packaging & Detailing Reports

Free Alert Me service